Indian generics manufacturer MSN Pharmaceuticals’ recent US Food and Drug Administration approval for a generic version of Vanda Pharmaceuticals’ Hetlioz (tasimelteon) was “unlawful and poses serious safety risks to public health,” because the agency in approving it disregarded its own “accepted principles of bioequivalence,” according to a lawsuit filed against the FDA by the originator.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?